Hemolyticuremic Syndrome Associated with Paclitaxellipsome: A Case Report and Review of Literature

LI Li,LIU Bao-rui,YUE Xiang
DOI: https://doi.org/10.3969/j.issn.1672-4992.2008.02.051
2008-01-01
Journal of Modern Oncology
Abstract:Objective:Paclitaxel is a new antitumor drug which has been used in first line chemotherapy of non-small cell lung cancer(NSCLC).The major side effect is hypersensitive reaction, but hemolytic-uremic syndrome (HUS) is rare . We present a case of HUS that developed during the first cycle of combination chemotherapy with paclitaxel-lipsome and cisplantin. Methods: A 54-year-old female was administered chemotherapy with paclitaxel-lipsome and cisplantin for a stage Ⅲa NSCLC. At the beginning of the first cycle chemotherapy,the patient developed clinical and laboratory abnormalities consistent with the development of the HUS. Results: Chemotherapy was discontinued, the patient was managed with plasma exchange and so on. Finally the patient recovered completely. Conclusion:The HUS is a rare complication of paclitaxel-based chemotherapy. Clinicians need to maintain a high index of suspicion to diagnose and treat this life-threatening adverse event.
What problem does this paper attempt to address?